@techreport{oai:mie-u.repo.nii.ac.jp:00015257,
 author = {井上, 貴博 and Inoue, Takahiro and 後藤, 崇之 and Goto, Takayuki and 中山, 憲司 and Nakayama, Kenji and 清水, 公治 and Shimizu, Koji and 加藤, 学 and Kato, Manabu and 佐々木, 豪 and Sasaki, Takeshi and 山崎, 俊成 and Yamasaki, Toshinari and 澤田, 篤郎 and Sawada, Atsuro},
 month = {May},
 note = {application/pdf, 前立腺癌細胞株に含有するPhosphatidylcholine (PC)のtargeted lipidomics を行い、浸潤能の高い前立腺癌株で不飽和脂肪酸の割合が多いことを見いだした。前立腺癌・前立腺肥大症患者尿中の脂質組成変化や揮発性有機化合物を質量分析法で解析し、前者で PCs/LPC 比が前立腺癌患者で有意に高値であることを見いだした。脂質過酸化経路に関わるAKR1C3が前立腺癌組織内や治療抵抗性とともにその発現の上昇が有ることを報告し、AKR1C3の阻害作用物質を含有するグリーンプロポリスを限局性前立腺癌術後PSA再発症例に投与する前向き臨床試験を行った。, Targeted lipidomics focused on the phosphatidylcholine (PC) species using preparative mass spectrometry (MS) was performed. The two more aggressive cell lines, PC3 and DU145, had higher percentages of polyunsaturated fatty acids (PUFA)s in their PC than LNCaP. We evaluated urinary lipids and volatile organic compounds by MS and found that the urinary PCs/LPC ratio quantified by MALDI/TOF-MS was significantly higher in the PCa group than in the BPH group in the discovery and validation sets. AKR1C3, which has some role in lipid peroxidation pathway, was significantly stronger expressed by immunostainings than the benign epithelia in patients with localized hormone naive prostate cancer (PC). Moreover, AKR1C3 immunostaining was significantly stronger in castration-resistant PC tissues than in HNPC tissues in the same patients. This single-center, single-arm open trial was conducted for 22 patients who underwent radical prostatectomy and experienced biochemical recurrence., 2018年度～2020年度科学研究費補助金(基盤研究(B))研究成果報告書, 18H02936},
 title = {脂質代謝異常に着目した新規前立腺癌診断・治療の開発},
 year = {2021},
 yomi = {イノウエ, タカヒロ and ゴトウ, タカユキ and ナカヤマ, ケンジ and シミズ, コウジ and カトウ, マナブ and ササキ, タケシ and ヤマサキ, トシナリ and サワダ, アツロウ}
}